8-K: Bionomics Re-domiciliation to the U.S. Approved by Supreme Court of New South Wales

The Supreme Court of New South Wales has approved Bionomics' re-domiciliation to the U.S., with Neuphoria Therapeutics Inc. becoming the parent company.

Summary

• Bionomics Limited has received court approval for its re-domiciliation from Australia to the United States.
• The re-domiciliation will be achieved through a Scheme of Arrangement, making Neuphoria Therapeutics Inc. the ultimate parent company.
• The Supreme Court of New South Wales approved the Scheme on December 16, 2024, and it became legally effective upon lodgement with the Australian Securities & Investments Commission.
• Bionomics ADSs will continue to trade on Nasdaq until December 23, 2024.
• Neuphoria shares are expected to begin trading on Nasdaq under the symbol NEUP on December 24, 2024, or as soon as possible thereafter.
• Bionomics shareholders who hold shares on the record date of December 17, 2024, will receive the Scheme consideration on the implementation date.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful court approval of the re-domiciliation, which is a key milestone for the company. The transition is progressing as planned, and the company is moving forward with its strategic objectives.

Positives

• The court approval marks a significant step in the re-domiciliation process.
• The re-domiciliation is expected to provide strategic benefits for the company.
• The transition to Neuphoria is expected to be completed quickly with trading of the new entity expected to commence on December 24, 2024.

Risks

• The actual trading date of Neuphoria shares may be delayed beyond December 24, 2024.
• There are inherent risks and uncertainties in the company's business that could affect future results.

Future Outlook

Neuphoria shares are expected to begin trading on Nasdaq under the symbol NEUP on December 24, 2024, or as soon as possible thereafter.

Management Comments

• Bionomics is pleased to announce that the Supreme Court of New South Wales, Australia (Court) has today made orders approving the scheme of arrangement in relation to the Company's proposed re-domiciliation from Australia to the United States (Scheme).

Industry Context

This re-domiciliation is a strategic move for Bionomics, potentially providing access to a larger investor base and more favorable market conditions in the U.S. It is not uncommon for international companies to re-domicile to the US to access capital markets.

Comparison to Industry Standards

• Re-domiciliation is a complex process, and the successful court approval indicates that Bionomics has met the necessary legal and regulatory requirements.
• The timeline for the re-domiciliation, from agreement to expected trading of Neuphoria shares, is relatively standard for such transactions.
• Other companies that have re-domiciled to the US include Jazz Pharmaceuticals and Shire, both of which saw increased access to capital and a higher valuation.

Stakeholder Impact

• Shareholders will receive Scheme consideration and will become shareholders of Neuphoria.
• Employees will likely see a change in the parent company structure.
• Customers and suppliers may experience minimal impact from the re-domiciliation.

Next Steps

• Bionomics ADSs will cease trading on Nasdaq on December 23, 2024.
• Neuphoria shares are expected to begin trading on Nasdaq on December 24, 2024, or as soon as possible thereafter.
• Scheme consideration will be paid to eligible shareholders on the implementation date.

Key Dates

Keywords

Re-domiciliation, Bionomics, Neuphoria, Scheme of Arrangement, Nasdaq, Supreme Court of New South Wales, Shareholders, ADSs, NEUP, BNOX